<DOC>
	<DOC>NCT00703911</DOC>
	<brief_summary>This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.</brief_summary>
	<brief_title>Observational Registry of NovoSevenÂ® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed with haemophilia A or B with inhibitors Experience mild to moderate spontaneous bleeds which require ondemand treatment and who are currently prescribed activated recombinant human factor VII Be able and willing to provide informed consent (or proxy consent by caregiver, if applicable), as required by local research ethics committee, governmental or regulatory authorities Be willing to provide information on at least one alternate contact person in the event that the patient be somehow losttofollowup over the course of registry participation (not applicable if patient is withdrawn) Known hypersensitivity to the active substance or the excipients in the formulation of activated recombinant human factor VII, or to mouse, hamster or bovine protein</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>